Pharmacokinetics, Safety, and Lung Deposition of 99mTc-DTPA Delivered Via the EDDIS System in Healthy Volunteers

Inclusion Criteria: * Age between 18 and 45 years * Healthy adults with no clinically significant medical history * Normal spirometry (FEV1 ≥ 80% predicted) * Body Mass Index (BMI) between 18.5 and 29.9 kg/m² * No prior exposure to radiopharmaceuticals in the past 12 months * Able and willing to comply with study procedures and provide written informed consent * Current or past use of tobacco products or electronic nicotine delivery systems (e.g., e-cigarettes) is not an exclusion criterion Exclusion Criteria: * History of asthma, COPD, or other chronic respiratory conditions * History of lung surgery, pulmonary embolism, or interstitial lung disease * Any ongoing respiratory infection or fever ≥ 38.0°C at screening or study day * Uncontrolled or progressive arterial hypertension * Known cardiovascular disease (e.g., arrhythmia, ischemic heart disease, heart failure) * Presence of blood in saliva, hemoptysis, or any known pulmonary bleeding * Diagnosed pulmonary emphysema * Known coagulation disorders or use of anticoagulant therapy * History of hypersensitivity to perfluorocarbons, DTPA, or radiopharmaceutical agents * Prior exposure to radiopharmaceuticals within the last 12 months * Participation in another clinical trial within the last 60 days * Pregnancy or breastfeeding * Use of any investigational or prescription drug within 30 days prior to study drug administration * Any condition which, in the opinion of the investigator, would pose a health risk or interfere wi…